BioCentury | Feb 2, 2021
Deals

Feb. 1 Quick Takes: Coherus gets rights to Junshi’s PD-1; plus GSK backs newco Adrestia, a seed for Cellino and more

...round. Investors included Samsung Venture Investment Corp., Shinhan Venture Investment, Smilegate Investment, Shinhan Investment Corp., Kolon...
BioCentury | Dec 19, 2019
Finance

Boehringer deal, clinical milestones support Bridge IPO

...for investors’ decision was the quality partnering deal with Boehringer.” James Lee, Bridge In June, Kolon Life Science Inc....
...cell therapy was derived from kidney cells rather than cartilage cells as its label claimed. Kolon...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

...at a $5.8 billion valuation. Bringing up the rear of the $1-$4.9 billion group was Kolon...
...FDA issues a complete response letter for HTX-011 to manage postoperative pain Kolon Life Science Inc. (KOSDAQ:102940) / Kolon...
...NASDAQ:INSY), Phoenix, Az. Iovance Biotherapeutics Inc. (NASDAQ:IOVA), San Carlos, Calif. Kolon Life Science Inc. (KOSDAQ:102940), Gwacheon, South Korea Kolon...
BioCentury | Jun 4, 2019
Company News

June 4 Company Quick Takes: Lilly's Emgality gets expanded indication; plus Vimizim, Zerbaxa and more

...expect FDA to make a decision within its standard review period. Korea revokes license for Kolon's...
...therapy South Korea's Ministry of Food and Drug Safety canceled the license for Invossa from Kolon Life Science Inc....
...derived from kidney cells, rather than cartilage cells as its label claimed. In April, partner Kolon...
BioCentury | Apr 4, 2019
Clinical News

Kolon TissueGene tumbles on mislabeling revelation for cell therapy Invossa

...TGFB1-expressing component is derived from kidney cells rather than cartilage cells as it previously thought. Kolon...
...and is down 42% since it announced the news in a regulatory filing Monday. Partner Kolon Life Science Inc....
...1 (TGFB1). Kolon TissueGene had thought the TGFB1-expressing cells used in the therapy were chondrocytes. Kolon...
BioCentury | Jul 13, 2017
Clinical News

TissueGene therapy gets Korean approval for OA

...approved regenerative therapy Invossa-K Inj. (TissueGene-C, TG-C) to treat osteoarthritis (OA) of the knee. Partners Kolon Life Science Inc....
...human chondrocytes and allogeneic human chondrocytes expressing transforming growth factor (TGF) beta 1 (TGFB1) . Kolon...
...April deal, Mundipharma is marketing and distributing the product to general and semi-private hospitals, and Kolon...
BioCentury | Jul 12, 2017
Company News

TissueGene therapy gets Korean approval for OA

...Md.) said Korea approved regenerative therapy Invossa-K Inj. to treat osteoarthritis of the knee. Partners Kolon Life Science Inc....
...human chondrocytes and allogeneic human chondrocytes expressing transforming growth factor (TGF) beta 1 (TGFB1) . Kolon...
...April deal, Mundipharma is marketing and distributing the product to general and semi-private hospitals, and Kolon...
BioCentury | Dec 9, 2016
Financial News

T cell play Eutilex raises W21B in series A

...Korea) raised W21 billion ($18.9 million) in a series A round from DS Asset Management, Kolon...
BioCentury | Dec 9, 2016
Financial News

Eutilex completes venture financing

...Eutilex raised W21 billion ($18.9 million) in a series A round from DS Asset Management, Kolon...
BioCentury | Nov 4, 2016
Company News

Kolon, Mitsubishi Tanabe Deal

...and commercialize Invossa , which is in development to treat osteoarthritis (OA) of the knee. Kolon...
...human chondrocytes and allogeneic human chondrocytes expressing transforming growth factor (TGF) beta 1 (TGFB1) . Kolon...
...Asian rights from TissueGene Inc. (Rockville, Md.) to develop and commercialize Invossa to regenerate cartilage. Kolon Life Science Inc....
Items per page:
1 - 10 of 16
BioCentury | Feb 2, 2021
Deals

Feb. 1 Quick Takes: Coherus gets rights to Junshi’s PD-1; plus GSK backs newco Adrestia, a seed for Cellino and more

...round. Investors included Samsung Venture Investment Corp., Shinhan Venture Investment, Smilegate Investment, Shinhan Investment Corp., Kolon...
BioCentury | Dec 19, 2019
Finance

Boehringer deal, clinical milestones support Bridge IPO

...for investors’ decision was the quality partnering deal with Boehringer.” James Lee, Bridge In June, Kolon Life Science Inc....
...cell therapy was derived from kidney cells rather than cartilage cells as its label claimed. Kolon...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

...at a $5.8 billion valuation. Bringing up the rear of the $1-$4.9 billion group was Kolon...
...FDA issues a complete response letter for HTX-011 to manage postoperative pain Kolon Life Science Inc. (KOSDAQ:102940) / Kolon...
...NASDAQ:INSY), Phoenix, Az. Iovance Biotherapeutics Inc. (NASDAQ:IOVA), San Carlos, Calif. Kolon Life Science Inc. (KOSDAQ:102940), Gwacheon, South Korea Kolon...
BioCentury | Jun 4, 2019
Company News

June 4 Company Quick Takes: Lilly's Emgality gets expanded indication; plus Vimizim, Zerbaxa and more

...expect FDA to make a decision within its standard review period. Korea revokes license for Kolon's...
...therapy South Korea's Ministry of Food and Drug Safety canceled the license for Invossa from Kolon Life Science Inc....
...derived from kidney cells, rather than cartilage cells as its label claimed. In April, partner Kolon...
BioCentury | Apr 4, 2019
Clinical News

Kolon TissueGene tumbles on mislabeling revelation for cell therapy Invossa

...TGFB1-expressing component is derived from kidney cells rather than cartilage cells as it previously thought. Kolon...
...and is down 42% since it announced the news in a regulatory filing Monday. Partner Kolon Life Science Inc....
...1 (TGFB1). Kolon TissueGene had thought the TGFB1-expressing cells used in the therapy were chondrocytes. Kolon...
BioCentury | Jul 13, 2017
Clinical News

TissueGene therapy gets Korean approval for OA

...approved regenerative therapy Invossa-K Inj. (TissueGene-C, TG-C) to treat osteoarthritis (OA) of the knee. Partners Kolon Life Science Inc....
...human chondrocytes and allogeneic human chondrocytes expressing transforming growth factor (TGF) beta 1 (TGFB1) . Kolon...
...April deal, Mundipharma is marketing and distributing the product to general and semi-private hospitals, and Kolon...
BioCentury | Jul 12, 2017
Company News

TissueGene therapy gets Korean approval for OA

...Md.) said Korea approved regenerative therapy Invossa-K Inj. to treat osteoarthritis of the knee. Partners Kolon Life Science Inc....
...human chondrocytes and allogeneic human chondrocytes expressing transforming growth factor (TGF) beta 1 (TGFB1) . Kolon...
...April deal, Mundipharma is marketing and distributing the product to general and semi-private hospitals, and Kolon...
BioCentury | Dec 9, 2016
Financial News

T cell play Eutilex raises W21B in series A

...Korea) raised W21 billion ($18.9 million) in a series A round from DS Asset Management, Kolon...
BioCentury | Dec 9, 2016
Financial News

Eutilex completes venture financing

...Eutilex raised W21 billion ($18.9 million) in a series A round from DS Asset Management, Kolon...
BioCentury | Nov 4, 2016
Company News

Kolon, Mitsubishi Tanabe Deal

...and commercialize Invossa , which is in development to treat osteoarthritis (OA) of the knee. Kolon...
...human chondrocytes and allogeneic human chondrocytes expressing transforming growth factor (TGF) beta 1 (TGFB1) . Kolon...
...Asian rights from TissueGene Inc. (Rockville, Md.) to develop and commercialize Invossa to regenerate cartilage. Kolon Life Science Inc....
Items per page:
1 - 10 of 16